Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma

Japanese Journal of Cancer Research

Volumn 89, Issue 2, 1998, Pages 221-227

  Suzuki, Akio ^a   Toi, Masakazu ^a   Yamamoto, Yutaka ^a   Saji, Shigehira ^a   Muta, Mariko ^a   Tominaga, Takeshi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Doxorubicin; MDM2; p21(Waf1); p53

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ESTRADIOL; FLUOROURACIL; MEDROXYPROGESTERONE ACETATE; ONCOPROTEIN; PROTEIN P21; VINCRISTINE;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CLINICAL ARTICLE; DNA DAMAGE; DOUBLE MINUTE CHROMOSOME; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031890636     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00552.x     Document Type: Article

References (38)

1. Cahilly-Snyder, L., Yang-Feng, T., Francke, U. and George, D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet., 13, 235-244 (1987).
2. Fakharzadeh, S. S., Trusko, S. P. and George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10, 1565-1569 (1991).
3. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83 (1992).
4. Momand, J., Ambetti, G. P., Olson, D. C., George, D. and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245 (1992).
5. Barak, Y., Juven, T., Haffner, R. and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 12, 461-468 (1993).
6. Wu, X., Bayle, J. H., Olso, D. and Levine, A. J. The p53-mdm2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132 (1993).
7. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R. and Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 375, 694-698 (1995).
8. Martin, K., Trouche, D., Hagemeier, C., Sørensen, T. S., Thangue, N. B. and Kouzarides, T. Stimulation of E2F/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375, 691-694 (1995).
9. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W. and Vogelstein, B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53, 2231-2234 (1993).
10. Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W.-J., Takahashi, R., Sugiyama, T. and Yoshida, O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst., 86, 1331-1335 (1994).
11. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E. and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53, 2736-2739 (1993).
12. Waber, P. G., Chen, J. and Nisen, P. D. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res., 53, 6028-6030 (1993).
13. Quesnel, B., Preudhomme, C., Fourneier, J., Fenaux, P. and Peyrat, J.-P. MDM2 gene amplification in human breast cancer. Eur. J. Cancer, 30, 982-984 (1994).
14. Inada, K., Toi, M., Yamamoto, Y., Suzuki, A., Kurisaki, T., Suzuki, H. and Tominaga, T. Immunocytochemical analysis of MDM2 protein expression and its relevance to tumor angiogenesis in primary breast cancer. Oncol. Rep., 3, 667-671 (1996).
15. Lianes, P., Orlow, I., Zhang, Z. F., Oliva, M. R., Sarkis, A. S., Reuter, V. E. and Cordon-Cardo, C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst., 86, 1325-1330 (1994).
16. Marchetti, A., Buttitta, F., Gilando, S., Palma, P. D., Pellegrini, S., Fina, P., Douglioni, C., Bevilacqua, G. and Barbareschi, M. mdm2 gene alterations and mdm2 protein expression in breast carcinoma. J. Pathol., 175, 31-38 (1995).
17. Baunoch, D. A., Watkins, L. F., Tewari, A., Reece, M. T., Adams, L., Stack, R., Brown, A., Jones, L., Christian, D., Latif, N. A., Lawrence, W. D. and Lane M. A. MDM2 overexpression in benign and malignant lesions of the human breast: association with ER expression. Int. J. Oncol., 8, 895-899 (1996).
18. Gudas, J. M., Nguyen, H., Klein, R. C., Katayose, D., Seth, P. and Cowan, K. H. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin. Cancer Res., 1, 71-80 (1995).
19. Sheikh, M. S., Shao, Z. M., Hussain, A. and Fontana, J. A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res., 53, 3226-3228 (1993).
20. Sigalas, I., Calvert, H., Anderson, J. J., Neal, D. E. and Lunec, J. Alteratively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2, 912-917 (1996).
21. Aas, T., Borrensen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. and Lonnin, P. E. Specific P53 mutations we associated with de nova resistance to doxorubicin in breast cancer patients. Nat. Med., 2, 811-814 (1996).
22. Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R., Martinetz-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M., Burki, K., Castiglione, M., Collins, J., Lindtner, J. and Senn, H. J. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol., 10, 1049-1056 (1992).
23. Bartek, J., Iggo, R., Gannon, J. and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5, 893-899 (1990).
24. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. Waf1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
25. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B. and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805 (1994).
26. Miyashita, T., Harigai, M., Hanada, M. and Reed, J. C. Identification of a p53 dependent negative response element in the bcl-2 gene. Cancer Res., 54, 3131-3135 (1994).
27. Pritsche, M., Haesseler, C. and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307-318 (1993).
28. Roemer, K. and Friedmann, T. Modulation of cell proliferation and gene expression by a p53-estrogen receptor hybrid protein. Proc. Natl. Acad. Sci. USA, 90, 9252-9256 (1993).
29. Carmicheal, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchell, J. B. Evaluation of tetrazolium-based semi-automated colorimetric assay: assessment of radiosensitivity. Cancer Res., 47, 943-946 (1987).
30. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Earl Ruley, H., Fisher, D. E., Housman, D. E. and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810 (1994).
31. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J. M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H. J., Forrester, K. and Harris, C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10, 188-195 (1995).
32. Bakalkin, G., Yakovlena, T., Selivanova, G., Magnusson, K. P., Szekeley, L., Kisaleva, E., Klein, G., Terenius, L. and Wilman, K. G. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA, 91, 413-417 (1994).
33. Lee, S., Elenbaas, B., Levine, A. and Griffith, J. p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81, 1013-1020 (1995).
34. Jayarman, L. and Privis, C. Activation of p53 sequence-specific DNA binding by short single strand of DNA requires the p53 C-terminus. Cell, 81, 1021-1029 (1995).
35. Davis, P., Bazar, K., Huper, G., Lozano, G., Marks, J. and Iglehart, J. D. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene, 13, 1315-1322 (1996).
36. Kondo, S., Kondo, Y., Hara, H., Kaakaji, R., Peterson, J. W., Morimura, T., Takeuchi, J. and Barnett, G. H. mdm2 gene mediates the expression of mdr gene and P-glycoprotein in a human glioblastoma cell line. Br. J. Cancer, 74, 1263-1268 (1996).
37. Chen, J., Marechal, V. and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13, 4107-4144 (1993).
38. Boddy, M. N., Freemont, P. S. and Borden, K. L. B., The p53-associated protein MDM2 contains a newly characterized zinc-finger domain called the RING finger. Trends Biochem., 19, 188-189 (1994).